In addition, in lung cancer, the STAT pathways regulates apoptotic genes, inhibits cell growth and improves the treatment efficacy of EGFR-TKIs.41 Reports have indicated that combining EGFR-TKIs or chemotherapy with JAK/STAT pathways inhibitors could enhance antitumor efficacy and decrease drug resistance in NSCLC.42,43 The role of JAK/STAT pathways inhibitors in cisplatin resistance was studied in NSCLC cell lines and tumor xenograft models. Here, EGFR is linked to non-small cell lung carcinoma.